rpl803 Antibody

What is the difference between RPL3 and RPL3L antibodies?

RPL3 (Ribosomal Protein L3) and RPL3L (Ribosomal Protein L3-Like) represent related but distinct ribosomal proteins. RPL3 is a component of the large 60S ribosomal subunit involved in protein synthesis, while RPL3L is a specific variant of RPL3. Antibodies against these proteins are designed to target their respective unique epitopes. The RPL3L antibody specifically recognizes the amino acid sequence 280-360 of the RPL3L protein: "LNKKIFRIGR GPHMEDGKLV KNNASTSYDV TAKSITPLGG FPHYGEVNND FVMLKGCIAG TKKRVITLRK SLLVHHSRQA V" . Meanwhile, RPL3 antibodies target different epitopes within the RPL3 protein structure, such as regions within the center of the human RPL3 sequence .

What are the validated applications for RPL3/RPL3L antibodies?

Based on comprehensive validation studies, RPL3 antibodies have demonstrated efficacy in multiple research applications:

The RPL3 antibody has been positively tested in multiple sample types including Jurkat cells, human kidney tissue, HeLa cells, Raji cells, human placenta tissue, and mouse kidney tissue . The RPL3L antibody shows specific reactivity with human samples .

What is the molecular characterization of RPL3 protein targeted by these antibodies?

The RPL3 protein has a calculated molecular weight of 46/27 kDa, though the observed molecular weight in experimental conditions is typically 46 kDa . The protein is encoded by gene ID 6122 (NCBI) with GenBank accession number BC012786 and UniProt ID P39023 . Understanding these parameters is essential for proper interpretation of experimental results, particularly when using these antibodies for protein detection in Western blot applications.

How should antigen retrieval be optimized for immunohistochemistry with RPL3 antibodies?

For optimal antigen retrieval when using RPL3 antibodies in immunohistochemistry applications, researchers should implement a two-step optimization strategy. Primary recommendation is to perform antigen retrieval with TE buffer at pH 9.0. If results are suboptimal, an alternative approach using citrate buffer at pH 6.0 should be evaluated . This methodological consideration is critical as improper antigen retrieval can significantly impact epitope accessibility and result in false negatives or reduced signal intensity. Each tissue type may require individual optimization of retrieval conditions to maximize signal-to-noise ratio.

What strategies ensure specificity when using RPL3L antibodies for detecting the AA 280-360 region?

To ensure high specificity when detecting the AA 280-360 region of RPL3L, researchers should implement a multi-faceted validation strategy:

• Always include positive controls with known RPL3L expression (such as human samples, as the antibody is validated for human reactivity)

• Include negative controls where the protein is not expected to be expressed

• Validate results with alternative methods (e.g., if using WB, confirm with IHC or IF)

• Consider pre-absorption tests with the immunizing peptide to confirm specificity

• Use recombinant RPL3L protein with the AA 280-360 region as a competitive inhibitor to demonstrate binding specificity

The sequence-specific nature of this antibody (targeting "LNKKIFRIGR GPHMEDGKLV KNNASTSYDV TAKSITPLGG FPHYGEVNND FVMLKGCIAG TKKRVITLRK SLLVHHSRQA V") makes it particularly valuable for distinguishing RPL3L from related ribosomal proteins .

What are the optimal storage conditions for maintaining RPL3/RPL3L antibody activity?

For maximal retention of antibody activity, RPL3 antibodies should be stored at -20°C. The storage buffer typically contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . For long-term storage, aliquoting is unnecessary at -20°C, though it's recommended for antibodies repeatedly accessed. The RPL3 antibody in 20μl sizes typically contains 0.1% BSA as a stabilizer . When properly stored, these antibodies maintain stability for approximately one year after shipment. These specifications ensure reproducible results across extended research timelines.

How do I design experiments to differentiate between RPL3 and RPL3L expression in tissue samples?

To effectively differentiate between RPL3 and RPL3L expression patterns, implement a comprehensive experimental design using the following approach:

• Sequential section analysis: Perform IHC on sequential tissue sections using specific antibodies for each protein (e.g., rabbit polyclonal anti-RPL3 and mouse polyclonal anti-RPL3L)

• Dual immunofluorescence: Employ differently conjugated secondary antibodies (e.g., Alexa Fluor 594 for RPL3L and a different fluorophore for RPL3)

• Western blot comparison: Run parallel Western blots with identical samples using both antibodies, noting the expected molecular weight of 46 kDa for RPL3

• Quantitative validation: Implement qPCR to correlate protein expression with transcript levels

• Controls: Include tissues with known differential expression of RPL3 versus RPL3L

This systematic approach enables confident discrimination between these related proteins while minimizing the risk of cross-reactivity or misinterpretation.

What are common challenges in RPL3 antibody Western blotting and how can they be addressed?

When performing Western blot analysis with RPL3 antibodies, researchers commonly encounter several technical challenges:

Systematic optimization of these parameters will significantly improve detection specificity and reproducibility in Western blot applications.

How should I interpret contradictory results between different detection methods using RPL3 antibodies?

When faced with contradictory results across different detection methods (e.g., positive WB but negative IHC), implement this systematic evaluation protocol:

• Epitope accessibility assessment: Different fixation and processing methods can affect epitope accessibility. RPL3 antibodies may require specific antigen retrieval conditions (TE buffer pH 9.0) for IHC

• Method-specific validation: Verify that the antibody is validated for each specific application. The RPL3 antibody has distinct recommended dilutions for WB (1:2000-1:16000) versus IHC (1:50-1:500)

• Sample preparation variables: Consider how sample preparation differs between methods and how this might affect RPL3 detection

• Complementary approaches: Implement RNA-level detection methods to confirm expression independent of protein detection

• Alternative antibody clones: Test alternative antibodies targeting different epitopes within RPL3

This structured analytical approach transforms contradictory results into valuable insights about protein expression, processing, or localization.

How do reactivity profiles of different commercial RPL3/RPL3L antibodies compare?

Comprehensive analysis of commercial RPL3/RPL3L antibodies reveals distinct reactivity profiles that must be considered when selecting reagents for specific research applications:

This comparative analysis demonstrates the importance of selecting antibodies based on specific experimental requirements, including target species, application method, and epitope recognition.

What strategies exist for multiplexing RPL3 antibodies with other markers in complex tissue analysis?

For sophisticated multiplexing of RPL3 antibodies with other markers, researchers should implement these advanced strategies:

• Antibody host species planning: Select RPL3 antibodies from one host species (e.g., rabbit) and complementary markers from different species (e.g., mouse, goat) to enable simultaneous detection

• Sequential immunostaining: Apply tyramide signal amplification with heat-mediated antibody stripping between rounds

• Spectral unmixing: Utilize fluorophores with distinct spectral properties when using fluorescently-conjugated anti-RPL3L antibodies (available with Alexa Fluor 750, 647, and 594)

• Validation controls: Include single-stain controls for each antibody to verify specificity in the multiplexed context

• Digital analysis: Implement computational image analysis to quantify co-localization or expression relationships

These methodological approaches enable complex spatial and quantitative analyses of RPL3/RPL3L in relation to other cellular components.

How can RPL3/RPL3L antibodies contribute to understanding ribosomal biology in disease states?

RPL3/RPL3L antibodies offer unique opportunities to investigate ribosomal biology in pathological conditions through several methodological approaches:

• Differential expression analysis: Compare RPL3 versus RPL3L expression across normal and diseased tissues using immunohistochemistry (IHC dilution 1:50-1:500)

• Subcellular localization studies: Investigate potential mislocalization of ribosomal proteins in disease states using immunofluorescence (IF dilution 1:200-1:800)

• Protein-protein interaction networks: Employ immunoprecipitation (IP with 0.5-4.0 μg antibody per 1.0-3.0 mg lysate) to capture RPL3-associated complexes that may be altered in disease

• Post-translational modification analysis: Combine RPL3 antibodies with modification-specific antibodies to investigate regulatory changes

• Extraribosomal functions: Explore potential non-canonical roles of RPL3/RPL3L outside the ribosome context

This multifaceted approach enables comprehensive investigation of how ribosomal protein alterations contribute to disease pathogenesis.

What considerations apply when using RPL3 antibodies in single-cell analysis techniques?

When incorporating RPL3 antibodies into single-cell analysis platforms, researchers should address these methodological considerations:

• Antibody specificity validation: Confirm specificity at the single-cell level using known positive and negative cell populations

• Signal amplification strategies: Implement tyramide signal amplification or similar methods to enhance detection sensitivity for low-abundance targets

• Fixation optimization: Systematically evaluate fixation conditions to maximize epitope preservation while maintaining cellular morphology

• Multiplexing compatibility: When using RPL3 rabbit polyclonal antibodies, carefully design panels with antibodies from different host species

• Cross-platform validation: Correlate antibody-based detection with orthogonal methods such as RNA-seq at single-cell resolution

These methodological refinements enable reliable incorporation of RPL3/RPL3L detection into emerging single-cell analysis workflows.

How can I develop and validate custom RPL3 antibodies for specialized research applications?

For researchers developing custom RPL3 antibodies, implement this comprehensive development and validation pipeline:

• Epitope selection: Identify unique epitopes with low homology to related proteins. Consider the approach used for successful RPL3L antibodies targeting AA 280-360

• Immunization strategy: Use GST-tagged recombinant partial protein fragments as demonstrated for RPL3L immunogens

• Validation hierarchy:

  • Confirm reactivity against recombinant protein

  • Verify detection of endogenous protein in known positive samples (e.g., Jurkat cells, HeLa cells for RPL3)

  • Test in knockout/knockdown models

  • Validate across all intended applications (WB, IHC, IF)

• Cross-reactivity assessment: Test against related ribosomal proteins, particularly RPL3 versus RPL3L

• Application-specific optimization: Determine optimal working dilutions for each application (following ranges established for commercial antibodies)

This systematic approach ensures development of highly specific custom antibodies suitable for specialized research applications.